GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Other Operating Expense

Gensight Biologics (XPAR:SIGHT) Other Operating Expense : €4.34 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Other Operating Expense?

Gensight Biologics's Other Operating Expense for the six months ended in Dec. 2023 was €1.29 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €4.34 Mil.

Gensight Biologics's quarterly Other Operating Expense increased from Dec. 2022 (€1.59 Mil) to Jun. 2023 (€3.04 Mil) but then declined from Jun. 2023 (€3.04 Mil) to Dec. 2023 (€1.29 Mil).

Gensight Biologics's annual Other Operating Expense declined from Dec. 2021 (€4.95 Mil) to Dec. 2022 (€2.84 Mil) but then increased from Dec. 2022 (€2.84 Mil) to Dec. 2023 (€4.34 Mil).


Gensight Biologics Other Operating Expense Historical Data

The historical data trend for Gensight Biologics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics Other Operating Expense Chart

Gensight Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 3.86 4.95 2.84 4.34

Gensight Biologics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.57 1.25 1.59 3.04 1.29

Gensight Biologics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €4.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gensight Biologics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Gensight Biologics (XPAR:SIGHT) Business Description

Traded in Other Exchanges
Address
74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines